Home > Neurology > Adults, kids have different risks for antidepressant AEs by CYP2C19 status

Adults, kids have different risks for antidepressant AEs by CYP2C19 status


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
Pediatrics
Reuters Health - 24/11/2020 - Children who are normal metabolizers (NMs) based on CYP2C19 genotype are more likely to have adverse events (AE) with sertraline than are poor metabolizers (PMs) and intermediate metabolizers (IMs), according to new findings. In adults, the opposite is true, with slower metabolizers more likely to have AEs with sertraline, Dr. Katelyn M. Rossow of Vanderbilt University Medical Center (VUMC) in Nashville, Tennessee, told Reuters Health by phone. "This study really highlights the need for more research in this area, and particularly more research before we apply some of these adult-based pharmacogenomic guidelines to pediatric patients," she said. It's common for clinicians to interpret pharmacogenomic-panel results for children based on adult guidelines, she added. Up to a third of children on selective serotonin-reuptake inhibitors (SSRIs) have AEs, Dr. Rossow and her colleagues note in Pediatrics. Adults and children have differ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on